CORONANSECORONA Remedies LimitedHighPositive
Announced Thu, 28 May · 15:37 IST

CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Receipt of EU-GMP Certificate".

Regulatory Product ApprovalBusiness Updates View source PDF

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹1678.40
prior close
₹1700.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.3-0.3+0.5+0.8+1.7+1.3+2.6+5.7+11.0+17.1
Up moveDown movePending
AI summary

Corona Remedies has received EU-GMP Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) facility at Bhayla, Ahmedabad. The certifications follow an EUDRA GMP inspection conducted in April 2026. This accreditation enables the company to serve both Indian and regulated/semi-regulated global markets from these facilities, particularly expanding its Hormone portfolio internationally. The company positioned this as a milestone under its 'One World. One Quality' philosophy.

Likely market impact

EU-GMP certification opens doors to regulated markets like the EU, potentially boosting future export revenue and strengthening the company's global manufacturing credibility in hormone and oral solid dosage segments.